Page 662 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

640 PART IV Specific Malignancies in the Small Animal Patient

126. Pinczowski D, McLaughlin JK, Lackgren G, et al.: Occurrence of 147. Bell FW, Klausner JS, Hayden DW, et al.: Clinical and patho-
testicular cancer in patients operated on for cryptorchidism and logic features of prostatic adenocarcinoma in sexually intact and
inguinal hernia, J Urol 146:1291–1294, 1991. castrated dogs: 31 cases (1970-1987), J Am Vet Med Assoc 199:623–
VetBooks.ir 127. Looijenga LH, Van Agthoven T, Biermann K: Development of 148. Bennett TC, Matz BM, Henderson RA, et al.: Total prostatectomy
630, 1991.
malignant germ cells - the genvironmental hypothesis, Int J Dev
Biol 57:241–253, 2013.
128. Tandstad T, Smaaland R, Solberg A, et al.: Management of semino- as a treatment for prostatic carcinoma in 25 dogs, Vet Surg 47:367–
377, 2018.
matous testicular cancer: a binational prospective population-based 149. Waters DJ, Bostwick DG: Prostatic intraepithelial neoplasia occurs
study from the Swedish Norwegian testicular cancer study group, spontaneously in the canine prostate, J Urol 157, 1997.
J Clin Oncol 29:719–725, 2011. 150. Madewell BR, Gandour-Edwards R, DeVere-White RW: Canine
129. Aparicio J, delMuro G, Maroto P, et al.: Multicenter study evalu- prostatic intraepithelial neoplasia: is the comparative model rel-
ating a dual policy of postorchiectomy surveillance and selective evant? Prostate 58:314–317, 2004.
adjuvant single-agent carboplatin for patients with clinical stage I 151. Aquilina JW, McKinney L, Pacelli A, et al.: High grade prostatic
seminoma, Ann Oncol 14:867–872, 2003. intraepithelial neoplasia in military working dogs with and without
130. Oliver RT, mead GM, Rustin GJ, et al.: Randomized trial of car- prostate cancer, Prostate 36:189–193, 1998.
boplatin versus radiotherapy for stage I seminoma: mature results 152. Palmieri C, Lean FZ, Akter SH, et al.: A retrospective analysis of
on relapse and contralateral testis cancer rates in MRC TE19/ 111 canine prostatic samples: histopathological findings and clas-
EORTC 30982 study (ISRCTN27163214), J Clin Oncol 29: sification, Res Vet Sci 97:568–573, 2014.
957–962, 2011. 153. Bryan JN, Keeler MR, Henry CJ, et al.: A population study of
131. Motzer RJ, Nichols CJ, Margolin KA, et al.: Phase III randomized neutering status as a risk factor for canine prostate cancer, Prostate
trial of conventional-dose chemotherapy with or without high- 67:1174–1181, 2007.
dose chemotherapy and autologous hematopoietic stem-cell rescue 154. LeRoy BE, Nadella MV, Toribio RE, et al.: Canine prostate carci-
as first-line treatment for patients with poor-prognosis metastatic nomas express markers of urothelial and prostatic differentiation,
germ cell tumors, J Clin Oncol 25:247–256, 2007. Vet Pathol 41:131–140, 2004.
132. Obradovich J, Walshaw R, Goullaud E: The influence of castration 155. Smith J: Canine prostatic disease: a review of anatomy, pathology,
on the development of prostatic carcinoma in the dog: 43 cases, diagnosis, and treatment, Theriogenology 70:375–383, 2008.
J Vet Intern Med 1:183–187, 1987. 156. Mochizuki H, Shapiro SG, Breen M: Detection of BRAF mutation
133. Bell FW, Klausner JS, Hayden DW, et al.: Evaluation of serum in urine DNA as a molecular diagnostic for canine urothelial and
and seminal plasma markers in the diagnosis of canine prostatic prostatic carcinoma, PloS One 10:e0144170, 2015.
disorders, J Vet Intern Med 9:149–153, 1995. 157. Sorenmo KU, Goldschmidt M, Shofer F, et al.: Immunohisto-
134. Cornell KK, Bostwick DG, Cooley DM, et al.: Clinical and patho- chemical characterization of canine prostatic carcinoma and cor-
logical aspects of spontaneous canine prostate carcinoma: a retro- relation with castration status and castration time, Vet Comp Oncol
spective analysis of 76 cases, Prostate 45:173–183, 2000. 1:48–56, 2003.
135. Waters DJ, Sakr WA, Hayden DW, et al.: Workgroup 5: sponta- 158. Grieco V, Riccardi E, Rondena M, et al.: The distribution of oes-
neous prostate cancer in dogs and non-human primates, Prostate trogen receptors in normal, hyperplastic and neoplastic canine
36:64–67, 1998. prostate, as demonstrated immunohistochemically, J Comp Pathol
136. Weaver AD: Fifteen cases of prostatic carcinoma in the dog, Vet Rec 135:11–16, 2006.
109:71–75, 1981. 159. Leav I, Schelling KH, Adams JY, et al.: Role of canine basal cells in
137. Waters DJ, Shen S, Glickman LT, et al.: Prostate cancer risk and postnatal prostatic development, induction of hyperplasia, and sex
DNA damage: translational significance of selenium supplementa- hormone-stimulated growth; and the ductal origin of carcinoma,
tion in a canine model, Carcinogenesis 26:1256–1262, 2005. Prostate 48:210–224, 2001.
138. Maini A, Archer C, Wang CY, et al.: Comparative pathology of 160. Lai CL, vandenHam R, Mol J, et al.: Immunostaining of the andro-
benign prostatic hyperplasia and prostate cancer, Vivo 11:293–300, gen receptor and sequence analysis of its DNA-binding domain in
1997. canine prostate cancer, Vet J 181:256–260, 2009.
139. Usui T, Sakurai M, Nishikawa S, et al.: Establishment of a dog 161. Humphrey PA: Gleason grading and prognostic factors in carci-
primary prostate cancer organoid using the urine cancer stem cells, noma of the prostate, Mod Pathol 17:292–306, 2004.
Cancer Sci 108:2383–2392, 2017. 162. Young RH, Srigley JR, Amin MB, et al.: Tumors of the prostate
140. Keller JM, Schade GR, Ives K, et al.: A novel canine model for gland, seminal vesicles, male urethra, and penis. Atlas of tumor pathol-
prostate cancer, Prostate 73:952–959, 2013. ogy: third series, Fascicle 28, Washington D.C, 2000, Armed Forces
141. Elshafae SM, Kohart NA, Altstadt LA, et al.: The effect of a histone Institute of Pathology.
deacetylase inhibitor (AR-42) on canine prostate cancer growth 163. Di Donato G, Laufer-Amorim R, Palmieri C: Nuclear morphom-
and metastasis, Prostate 77:776–793, 2017. etry in histological specimens of canine prostate cancer: correlation
142. Kato Y, Ochiai K, Kawakami S, et al.: Canine REIC/Dkk-3 inter- with histological subtypes, Gleason score, methods of collection
acts with SGTA and restores androgen receptor signalling in andro- and survival time, Res Vet Sci 114:212–217, 2017.
gen-independent prostate cancer cell lines, BMC Vet Res 13:170, 164. Palmieri C, Grieco V: Proposal of Gleason-like grading system of
2017. canine prostate carcinoma in veterinary pathology practice, Res Vet
143. Rivera-Calderon LG, Fonseca-Alves CE, Kobayashi PE, et al.: Sci 103:11–15, 2015.
Alterations in PTEN, MDM2, TP53 and AR protein and gene 165. Lin HY, Palmieri C: Is STAT3 and PTEN expression altered in
expression are associated with canine prostate carcinogenesis, Res canine prostate cancer? J Comp Pathol 155:185–189, 2016.
Vet Sci 106:56–61, 2016. 166. Weisse C, Berent A, Todd K, et al.: Evaluation of palliative stenting
144. Hornbuckle WE, MacCoy DM, Allan GS, et al.: Prostatic disease for management of malignant urethral obstructions in dogs, J Am
in the dog, Cornell Vet 68:284–305, 1978. Vet Med Assoc 229:226–234, 2006.
145. Krawiec DR, Heflin D: Study of prostatic disease in dogs: 177 cases 167. Mainwaring CJ: Primary lymphoma of the prostate in a dog, J Sm
(1981-1986), J Am Vet Med Assoc 200:1119–1122, 1992. Anim Pract 31:617–619, 1990.
146. Teske E, Naan EC, vanDijk EM, et al.: Canine prostate carcinoma: 168. Winter MD, Locke JE, Penninck DG: Imaging diagnosis - urinary
epidemiological evidence of an increased risk in castrated dogs, Mol obstruction secondary to prostatic lymphoma in a young dog, Vet
Cell Endocrinol 197:251–255, 2002. Radiol Ultrasound 47:597–601, 2006.